Business Wire
22 Sept 2026, 11:45 UTC · 1h ago
Verdict
Headline takes no side. We score LTRN +0.80 across one claim — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Lantern Pharma received a USPTO Notice of Allowance for its LP-284 treatment patent targeting mantle cell lymphoma.
Newannounced today
More positive than 76% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 84% of ticker scores this week
The company received a Notice of Allowance from the USPTO for a patent related to its drug candidate LP-284.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
LTRN hasn't traded since this ran. Last close $1.50 (Sep 21); the reaction starts at the next open.
LTRN chart →